Immuron granted US Travelan patent


By Dylan Bushell-Embling
Wednesday, 23 October, 2013

Immuron (ASX:IMC) has been granted a new US patent covering products including Travelan, its preventative treatment for travellers’ diarrhoea.

The US Patents and Trademarks Office has issued a Notice of Allowance covering one of the company’s patent claims.

Immuron’s patent claims are focused on methods of treating enteric diseases with the company’s hyperimmune colostrum platform technology.

The company is also using the platform to develop treatments for other enteric diseases, including C. difficile and nonalcoholic steatohepatitis (NASH), and the newly granted patent also encompasses these other projects.

“It is reassuring to have this patent in place ... as we continue to progress with our substantive discussions in the United States for the commercialisation of Travelan and related products in the world’s largest market for pharmaceuticals,” Immuron CEO Amos Meltzer said.

“We look forward to achieving further patents around our core technologies in the USA and other key jurisdictions.”

Immuron (ASX:IMC) shares were trading 40% higher at $0.007 as of around 2 pm on Wednesday.

Related News

Oxytocin analogue treats chronic abdominal pain

Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...

'Low-risk' antibiotic linked to rise of dangerous superbug

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

Robotic hand helps cultivate baby corals for reef restoration

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd